Isolation of human immunodeficiency virus type 2 from a homosexual man in Belgium

1988 ◽  
Vol 7 (6) ◽  
pp. 816-818 ◽  
Author(s):  
B. Vanderborght ◽  
R. J. Leys ◽  
P. Nijs ◽  
G. Groen ◽  
J. Merregaert ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Immunodeficiency Virus

Human immunodeficiency virus type 2 envelope glycoprotein: Differential CD4 interactions of soluble gpl20 versus the assembled envelope complex

Virology ◽  
1992 ◽  
Vol 187 (1) ◽  
pp. 233-241 ◽  
Author(s):  
Mark J. Mulligan ◽  
G.Douglas Ritter ◽  
Margery A. Chaikinj ◽  
Galina V. Yamshchikov ◽  
Prasanna Kumar ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Envelope Glycoprotein ◽  
Immunodeficiency Virus

Genetic Variation in Human Immunodeficiency Virus Type 2: Identification of a Unique Variant from Human Plasma

1997 ◽  
Vol 13 (5) ◽  
pp. 401-404 ◽  
Author(s):  
CATHERINE A. BRENNAN ◽  
JULIE YAMAGUCHI ◽  
ANA S. VALLARI ◽  
ROBERT K. HICKMAN ◽  
SUSHIL G. DEVARE
Keyword(s):  
Human Immunodeficiency Virus ◽  
Genetic Variation ◽  
Human Plasma ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Immunodeficiency Virus

scholarly journals Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection

Virology ◽  
2003 ◽  
Vol 308 (2) ◽  
pp. 225-232 ◽  
Author(s):  
Qin Lizeng ◽  
Pia Skott ◽  
Samer Sourial ◽  
Charlotta Nilsson ◽  
S.ören Andersson ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Immunoglobulin A ◽  
Serum Immunoglobulin ◽  
Immunodeficiency Virus

scholarly journals Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys

2001 ◽  
Vol 82 (7) ◽  
pp. 1601-1612 ◽  
Author(s):  
Lilian Walther-Jallow ◽  
Charlotta Nilsson ◽  
Johan Söderlund ◽  
Peter ten Haaft ◽  
Barbro Mäkitalo ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Simian Immunodeficiency Virus ◽  
Virus Replication ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Cross Protection ◽  
Parallel Group ◽  
Immunodeficiency Virus ◽  
Siv Infection

In this study we compared the efficacy of live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol). Six monkeys were first inoculated intravenously with live HIV-2SBL-6669 and 7 to 10 months later were challenged intrarectally with 10 MID50 of cell-free simian immunodeficiency virus (SIV) strain SIVsm. One monkey was completely protected against SIV infection and all five monkeys that became SIV-infected showed a lower virus replication and an initial lower virus load as compared with a parallel group of six control animals. In another experiment five monkeys were immunized either three times with ALVAC HIV-2 alone or twice with ALVAC HIV-2 and once with purified native HIV-2 gp125. The monkeys were then challenged with HIV-2 given intravenously and finally with pathogenic SIVsm given intrarectally. After challenge with SIVsm, three of five monkeys were completely protected against SIVsm infection whereas the remaining two macaques became SIV-infected but with limited virus replication. In conclusion, vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only.

Sign in / Sign up

Export Citation Format

Share Document